The new 2026 Yamaha YZF-R7 will be available in Team Yamaha Blue, Raven Black or Breaker Cyan/Raven for $9,399 MSRP and will begin arriving to dealers in February 2026. The new 2026 Yamaha YZF-R7 70th ...
As global markets evolve and financial risks continue to rise, ProtectYou.com, the online resource of Donlevy-Rosen & Rosen, P.A., has announced the release of a comprehensive framework designed to ...
Marking ECD’s first-ever Porsche 911 build, Project Gravette made its public debut at the event and immediately captivated spectators and judges alike with its flawless craftsmanship, modern ...
Recognition underscores Aptiv's pioneering approach to intelligent perception and automation through its innovative PULSE Sensor, advancing Product Leadership in Automotive Assisted Parking ...
Through this operation, the company expands its packaging offering for the pharmaceutical and veterinary sectors in Spain ...
DIVEVOLK, a leader in underwater imaging and diving technology, today announced the launch of the SeaTouch 4 Max Platinum V2, a significant upgrade to its flagship underwater smartphone housing.
"The addition of Achieve One reflects Presidio’s disciplined approach to growth through culturally aligned acquisitions,” said Bob Cagnazzi, CEO of Presidio. "Their technical excellence, strong ...
Based on our Q3 and 9M results, our full-year financial guidance for 2025 is narrowed to: This document is an unofficial translation of the Danish original. In the event of any inconsistencies, the ...
Gevo, Inc. (NASDAQ: GEVO) is pleased to announce that it has completed the sale transaction of Agri-Energy, LLC ('Agri”), a wholly owned subsidiary of Gevo, to A.E. Innovation, LLC ('A.E.”). The ...
Transaction Values WorkSimpli at $65 Million Enterprise Value; Supports LifeMD’s Strategic Focus on Scaling its Virtual Care and Pharmacy Businesses ...
Project Gravette joins ECD’s growing roster of award-winning builds in 2025, following The Wellesley Commission Jaguar E-Type and Project Ghost Mustang, both recognized for their design and ...
AIM ImmunoTech Inc. (NYSE American: AIM) ('AIM” or the 'Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback